RabMAb

Anti-Apolipoprotein A I antibody [EP1368Y] (ab52945)

Overview

  • Product nameAnti-Apolipoprotein A I antibody [EP1368Y]
    See all Apolipoprotein A I primary antibodies
  • Description
    Rabbit monoclonal [EP1368Y] to Apolipoprotein A I
  • Tested applicationsSandwich ELISA, WB, IP, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Human

    Does not react with

    Mouse, Rat
  • Immunogen

    A synthetic peptide corresponding to residues near the N-terminus of human Apolipoprotein A I

  • Positive control
    • Fetal liver lysate, human liver tissue and HEPG2 cells.
  • General notes

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Applications

Our Abpromise guarantee covers the use of ab52945 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA 1/2000 - 1/4000. Can be paired for Sandwich ELISA with Rabbit polyclonal to Apolipoprotein A I (ab33470). PubMed: 20421239
WB 1/20000. Detects a band of approximately 31 kDa (predicted molecular weight: 31 kDa).
IP 1/60.
IHC-P Use at an assay dependent dilution.
ICC/IF 1/100 - 1/250.
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionParticipates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
    • Tissue specificityMajor protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
    • Involvement in diseaseDefects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
      Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
      Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
      Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
    • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
    • Post-translational
      modifications
      Palmitoylated.
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localizationSecreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • Apo AI antibody
      • Apo-AI antibody
      • ApoA I antibody
      • ApoA-I antibody
      • APOA1 antibody
      • APOA1/APOC3 fusion gene antibody
      • APOA1_HUMAN antibody
      • Apolipoprotein A I precursor antibody
      • Apolipoprotein A-I(1-242) antibody
      • Apolipoprotein A1 antibody
      • Apolipoprotein AI antibody
      • Apolipoprotein of high density lipoprotein antibody
      • ApolipoproteinAI antibody
      • Brp14 antibody
      • Ltw1 antibody
      • Lvtw1 antibody
      • MGC117399 antibody
      • Sep1 antibody
      • Sep2 antibody
      see all

    Anti-Apolipoprotein A I antibody [EP1368Y] images

    • Anti-Apolipoprotein A I antibody [EP1368Y] (ab52945) at 1/20000 dilution + fetal liver lysate at 10 µg

      Secondary
      goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size : 31 kDa
      Observed band size : 31 kDa
    • ab52945 at 1/100 dilution staining Apolipoprotein A I in human liver by Immunohistochemistry, Paraffin embedded tissue.
    • ab52945 at 1/100 dilution staining Apolipoprotein A I in HEPG2 cells by Immunofluorescence.

    References for Anti-Apolipoprotein A I antibody [EP1368Y] (ab52945)

    This product has been referenced in:
    • Lukkahatai N  et al. Proteomic Serum Profile of Fatigued Men Receiving Localized External Beam Radiation Therapy for Non-Metastatic Prostate Cancer. J Pain Symptom Manage N/A:N/A (2013). Read more (PubMed: 23916682) »
    • Nguyen SD  et al. Spontaneous remodeling of HDL particles at acidic pH enhances their capacity to induce cholesterol efflux from human macrophage foam cells. J Lipid Res 53:2115-25 (2012). Read more (PubMed: 22855736) »

    See all 6 Publications for this product

    Product Wall

    Thank you for your enquiry and interest in our products.

    Currently, the blocking peptide for this particular antibody is not available commercially. However, if you wish to check the specificity I would advise to run a no-primary (only second...

    Read More

    Thank you for bringing this to our attention. I agree that your protocol appears correct and that the antibody may be at fault. We sometimes see an improvement in signal for some antibodies after switching the blocking buffer from 5% milk to BSA, but g...

    Read More

    Thank you for contacting us.

    I am sorry that the vial you received was not at the predicted concentration and I apologize for the inconvenience. I have issued a free of charge replacement vial with the order number of xxxxxx.


    Ple...

    Read More

    Thank you for contacting us. Yes, the Apolipoprotein A I protein ab90760 is the correct target for the antibodies ab52945 and ab20918. However, please note that the only data we have for sELISA are : - ab52945 has been used in sELISA in pair wi...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"